ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,240.03
      1.04%
      US Tech 100
      17,466.00
      0.29%
      Dow Jones
      38,997.66
      0.76%
      Brent Oil
      76.415
      0.52%
      Bitcoin
      56,892.07
      1.50%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AnaptysBio Inc (ANAB) Quote

      AnaptysBio Inc

      AnaptysBio Inc (ANAB)

      NASDAQ
      32.08
      -0.29
      (-0.90%)
      Closed August 07 4:00PM
      Delayed by 15 minutes
      32.08
      -0.01
      (-0.03%)
      After Hours: 4:20PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      32.08
      Bid
      13.72
      Ask
      122.00
      Volume
      240,235
      31.85 Day's Range 33.83
      13.36 52 Week Range 38.85
      Market Cap
      876.382M
      Previous Close
      32.37
      Open
      33.66
      Last Trade
      295
      @
      32.08
      (formt)
      Last Trade Time
      Financial Volume
      $ 7,911,852
      VWAP
      32.9338
      Average Volume (3m)
      320,322
      Shares Outstanding
      27,318,644
      Dividend Yield
      -
      PE Ratio
      -5.40
      Earnings Per Share (EPS)
      -5.99
      Revenue
      17.16M
      Net Profit
      -163.62M

      About AnaptysBio Inc

      AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.anaptysbio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was $32.37. Over the last year, AnaptysBio shares have traded in a share price range of $ 13.36 to $ 38.85.

      AnaptysBio currently has 27,318,644 shares outstanding. The market capitalization of AnaptysBio is $884.30 million. AnaptysBio has a price to earnings ratio (PE ratio) of -5.40.

      AnaptysBio (ANAB) Options Flow Summary

      ANAB Options Flow

      Overall Flow

      Bearish

      Net Premium

      -109k

      Calls / Puts

      0.00%

      Buys / Sells

      0.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      ANAB Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      9 hours ago
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      August 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 01 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-4.92-13.29729729733737.7530.8136819733.68491864CS
      46.5425.606891151125.5438.8524.9532914333.65042516CS
      127.8432.343234323424.2438.8522.2632032227.59306243CS
      268.0933.722384326823.9938.8518.4934080425.0585452CS
      5213.2570.366436537418.8338.8513.3630331222.44808208CS
      1568.1333.945720250523.9538.8513.3625622723.94778524CS
      260-18.92-37.09803921575154.199.1633219022.01740872CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      VBIVVBI Vaccines Inc
      $ 0.1291
      (105.25%)
      		423.92M
      LYTLytus Technologies Holdings PTV Ltd
      $ 2.15
      (52.48%)
      		26.93M
      CLNNClene Inc
      $ 5.9801
      (49.50%)
      		3.74M
      RCONRecon Technology Ltd
      $ 2.19
      (44.09%)
      		923.22k
      VSEEVSee Health Inc
      $ 3.575
      (33.90%)
      		19.83M
      ANTEAirNet Technology Inc
      $ 0.457
      (-80.88%)
      		12.19M
      RRRichtech Robotics Inc
      $ 0.374
      (-73.66%)
      		56M
      ELEVElevation Oncology Inc
      $ 0.7847
      (-63.16%)
      		19.32M
      TDUPThredUp Inc
      $ 0.6452
      (-62.71%)
      		8.11M
      SPECSpectaire Holdings Inc
      $ 0.164
      (-42.98%)
      		1.66M
      VBIVVBI Vaccines Inc
      $ 0.1291
      (105.25%)
      		423.92M
      NVDANVIDIA Corporation
      $ 104.25
      (3.78%)
      		410.11M
      SQQQProShares UltraPro Short QQQ
      $ 10.49
      (-2.78%)
      		271.93M
      PRSTPresto Technologies Inc
      $ 0.0304
      (11.36%)
      		109.36M
      INTCIntel Corporation
      $ 19.83
      (-1.39%)
      		106.47M

      ANAB Discussion

      View Posts
      gfp927z gfp927z 2 years ago
      HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

      Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

      ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




      ---
      👍️0
      HighPeaks HighPeaks 2 years ago
      Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
      👍️0
      tedpeele tedpeele 2 years ago
      Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

      Will be watching this closely...thanks.
      👍️0
      HighPeaks HighPeaks 2 years ago
      According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
      https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
      👍️0
      TFMG TFMG 4 years ago

      $ANAB | #Anaptysbio Spikes After Drug Designation


      Nice spike in the afterhours session, lets hope we
      can get some continuation tomorrow.
      Target $29.00 to Fib Golden Pocket
      Also a very large gap to fill at $35.00
      AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
      PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


      👍️0
      LoveItInBishop LoveItInBishop 5 years ago
      RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $ANAB Video Chart 11-13-19 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $ANAB Video Chart 11-08-19 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      waterchaser waterchaser 5 years ago
      LOL! Twitter PnD. Buyer beware.
      👍️0
      420man 420man 5 years ago
      Once the real bounce starts it will be fast....
      👍️0
      Crazy Money Crazy Money 5 years ago
      $10 to da moon
      👍️0
      420man 420man 5 years ago
      This will bounce..... 15 AH
      👍️0
      RJ Trotts RJ Trotts 5 years ago
      trying to bounce back over $11, hoping for more
      👍️0
      TaxiCaT TaxiCaT 5 years ago
      Ouch -
      👍️0
      celle celle 5 years ago
      Nothing happen here?
      👍️0
      manny371 manny371 7 years ago
      This stock is making noise! Bought in Sept $ANAB
      👍️0

      Your Recent History

      NASDAQ
      ANAB
      AnaptysBio
      TSX
      EIF
      Exchange Income
      Delayed Upgrade Clock